Commure Ends Customer Referral Payments for AI Product Promotions

Commure, a major health software company valued at $7 billion, has abruptly ended its customer referral program, which compensated parties for promoting its artificial intelligence tools to medical clinics. The move comes after internal emails revealed the company's decision to terminate the program, with payments to cease within 30 days of notice. According to emails obtained by STAT, Chief Legal Officer Dan Brian informed program members that their agreements would be terminated shortly. One email, dated August 6, assured that any outstanding payments would be settled in full by the termination date. The notice was sent just days before STAT published an investigation into Commure’s referral practices, which included offers of thousands of dollars to customers and other parties for promoting its AI products. ## Background of the Referral Program Commure’s referral program was designed to incentivize existing customers and other stakeholders to recommend its AI-driven health software to new medical clinics. The program, which had been operational for an unspecified period, provided financial rewards for successful referrals. However, the company’s decision to terminate it suggests a shift in strategy or a response to external scrutiny. STAT’s investigation, which began with an inquiry to Brian on June 5, uncovered details of the referral arrangements, raising questions about the ethics and transparency of such practices in the health software industry. The timing of the termination notice, just before the publication of STAT’s findings, has led to speculation about whether the company was preempting potential criticism. ## Company Response and Implications In the emails, Brian did not provide a specific reason for the termination, but the move aligns with a broader trend in the health tech sector to reassess marketing practices. The referral program had been a key part of Commure’s growth strategy, but its abrupt end may reflect concerns about compliance or public perception. The termination of the program could have significant implications for Commure’s business model, particularly if the company relied heavily on referrals to attract new customers. It also raises questions about how other health software companies structure their marketing incentives and whether similar programs will face increased scrutiny in the future. As the health tech industry continues to evolve, Commure’s decision to end its referral payments may serve as a cautionary tale for other companies navigating the complex intersection of marketing, ethics, and regulatory compliance.